Naismith, Robert et al "EVOLVE-MS-1: A Phase 3, Open-Label, Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis (P6.360)." Neurology 90.15 Supplement (2018): P6.360. Web. 17 May. 2022.